Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 38.01% | 17.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.01% | 17.90% | |||
| Cost of Revenue | 41.83% | 0.31% | |||
| Gross Profit | 36.22% | 28.47% | |||
| SG&A Expenses | 19.20% | -1.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.95% | -1.13% | |||
| Operating Income | 2.94% | 24.44% | |||
| Income Before Tax | 1.31% | 29.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.31% | 29.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.31% | 29.65% | |||
| EBIT | 2.94% | 24.44% | |||
| EBITDA | 3.57% | 24.76% | |||
| EPS Basic | 1.77% | 30.67% | |||
| Normalized Basic EPS | 13.40% | 26.36% | |||
| EPS Diluted | 1.77% | 30.67% | |||
| Normalized Diluted EPS | 13.40% | 26.36% | |||
| Average Basic Shares Outstanding | 0.47% | 1.48% | |||
| Average Diluted Shares Outstanding | 0.47% | 1.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
